CRIS Current Research Information System

J. Bruix, P.M. (2017). Comparison of modified (m)RECISTand RECIST 1.1 assessments in the phase 3 RESORCE trial comparing regorafenib and placebo in patients with hepatocellular carcinoma who progressed during sorafenib treatment. JOURNAL OF HEPATOLOGY, 66(1), 451-452.

Comparison of modified (m)RECISTand RECIST 1.1 assessments in the phase 3 RESORCE trial comparing regorafenib and placebo in patients with hepatocellular carcinoma who progressed during sorafenib treatment.

A. Granito
Investigation
;
2017
2017
J. Bruix, P.M. (2017). Comparison of modified (m)RECISTand RECIST 1.1 assessments in the phase 3 RESORCE trial comparing regorafenib and placebo in patients with hepatocellular carcinoma who progressed during sorafenib treatment. JOURNAL OF HEPATOLOGY, 66(1), 451-452.
J. Bruix , P. Merle , A. Granito , Y.-H. Huang , G. Bodoky , M. Pracht , . Yokosuka , O. Rosmorduc , V. Breder , R. Gerolami , G. Masi , P....espandi
1.06 Abstract in rivista
File in questo prodotto:
Eventuali allegati, non sono esposti

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/720207
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact